AbbVie: Two new indications for Ruifu (Upatinib Extended Release Tablets) have been added to the national medical insurance catalog in China
六月清晨搅
发表于 2024-12-5 15:20:17
154
0
0
On November 28th, AbbVie China announced that the two newly approved indications for the immune innovation product Ruifu (Upatinib Extended Release Tablets) in 2023 have entered the new version of the national medical insurance catalog released on the same day, for the treatment of patients with ankylosing spondylitis (AS) and radiologically negative axial spondyloarthritis (nr-ax5pA).
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- Release two "super useful" AI technologies, the non consensus solution of Robin Lee, an AI longtime activist
- BeiGene: Several new indications for commercial products have been included in the 2024 National Medical Insurance Drug Catalog
- Novo Nordisk's world's first weekly insulin preparation, Novo Nordisk, has been included in the national medical insurance catalog
- AstraZeneca's "breast cancer ADC miracle drug" DS-8201 entered the new version of medical insurance directory
- Top 20 US stock transactions: Eli Lilly rises over 4%, Biden administration plans to include weight loss drugs in healthcare and subsidy programs
- It is reported that two major advertising giants, Hongmeng and Epeizhi, are in deep talks to merge or create the world's largest advertising group
- Multiple new indications for Merck drugs approved for market in China
- CEO shooting case hits two major fast food giants in the United States: McDonald's gains Google protection, Burger King inexplicably lies at gunpoint
- BeiGene and BeiZeAn are approved for new indications in the United States
